Table 3. Characteristics of patients who experienced a renal flare while on maintenance treatment .
MMF: mycophenolate mofetil, ESRD: end-stage renal disease
| Months on MMF | MMF continued after flare | Medication added at time of flare | Return to remission |
| 7 | Yes | Rituximab | Complete |
| 16 | Yes | Steroids | No -> ESRD |
| 19 | Yes | Cyclophosphamide | Complete |
| 22 | Yes | Rituximab | Partial |
| 36 | Yes | Increased MMF | Partial |
| 37 | No | Cyclophosphamide | Complete |
| 39 | Yes | Cyclophosphamide | Complete |
| 39 | Yes | Steroids | Partial |
| 48 | Yes | Steroids | Complete |
| 64 | Yes | steroids | Complete |